Literature DB >> 22360737

Pharmacoepidemiology.

Stephen J W Evans1.   

Abstract

Current concerns over the safety of medicines once they have been marketed mean that pharmacoepidemiology is of increasing importance. There are three main areas in which further research is needed. 1 To improve the methods used to make causal inference of effects of medicines and to raise the quality of the reporting and critical appraisal tools, so that the strengths and weaknesses of the new methods can be judged. 2 To apply the methods in areas where randomized trials cannot easily be done, such as in pregnancy. 3 To use electronic health records as fully as possible, using linkage between different databases, ensuring the data are of as high quality as possible. Public health and public perceptions mean that much of pharmacoepidemiology must be done using non-industry funding sources.
© 2012 The Author. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Mesh:

Year:  2012        PMID: 22360737      PMCID: PMC3391530          DOI: 10.1111/j.1365-2125.2012.04248.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  32 in total

Review 1.  Principles for modeling propensity scores in medical research: a systematic literature review.

Authors:  Sherry Weitzen; Kate L Lapane; Alicia Y Toledano; Anne L Hume; Vincent Mor
Journal:  Pharmacoepidemiol Drug Saf       Date:  2004-12       Impact factor: 2.890

2.  Cutting feedback in Bayesian regression adjustment for the propensity score.

Authors:  Lawrence C McCandless; Ian J Douglas; Stephen J Evans; Liam Smeeth
Journal:  Int J Biostat       Date:  2010       Impact factor: 0.968

3.  Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

4.  The case-crossover design: a method for studying transient effects on the risk of acute events.

Authors:  M Maclure
Journal:  Am J Epidemiol       Date:  1991-01-15       Impact factor: 4.897

Review 5.  Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice.

Authors:  Y G Weldeselassie; H J Whitaker; C P Farrington
Journal:  Epidemiol Infect       Date:  2011-08-18       Impact factor: 2.451

Review 6.  Estimating causal effects from large data sets using propensity scores.

Authors:  D B Rubin
Journal:  Ann Intern Med       Date:  1997-10-15       Impact factor: 25.391

7.  Relative incidence estimation from case series for vaccine safety evaluation.

Authors:  C P Farrington
Journal:  Biometrics       Date:  1995-03       Impact factor: 2.571

8.  The need for randomization in the study of intended effects.

Authors:  O S Miettinen
Journal:  Stat Med       Date:  1983 Apr-Jun       Impact factor: 2.373

9.  Overview of clinically significant adverse reactions to bupropion.

Authors:  J Van Wyck Fleet; P J Manberg; L L Miller; N Harto-Truax; T Sato; R J Fleck; W C Stern; A E Cato
Journal:  J Clin Psychiatry       Date:  1983-05       Impact factor: 4.384

10.  Risk of myocardial infarction and stroke after acute infection or vaccination.

Authors:  Liam Smeeth; Sara L Thomas; Andrew J Hall; Richard Hubbard; Paddy Farrington; Patrick Vallance
Journal:  N Engl J Med       Date:  2004-12-16       Impact factor: 91.245

View more
  4 in total

1.  Relevance of pharmacoepidemiology to Nepal.

Authors:  Santosh Thapa; Subish Palaian; Hisham Aljadhey; Pathiyil Ravi Shankar
Journal:  Australas Med J       Date:  2013-08-31

2.  Importance of feasibility assessments before implementing non-interventional pharmacoepidemiologic studies of vaccines: lessons learned and recommendations for future studies.

Authors:  Corinne Willame; Laurence Baril; Judith van den Bosch; Germano L C Ferreira; Rachael Williams; Dominique Rosillon; Catherine Cohet
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-09-07       Impact factor: 2.890

3.  [Intervention in the prescribing of the combination of an angiotensin converting enzyme inhibitor and an angiotensin-II receptor blocker].

Authors:  Alfredo Portilla; Daniel Torres; Manuel Enrique Machado-Duque; Jorge Enrique Machado-Alba
Journal:  Aten Primaria       Date:  2015-10-29       Impact factor: 1.137

4.  Data Sources for Drug Utilization Research in Brazil-DUR-BRA Study.

Authors:  Lisiane Freitas Leal; Claudia Garcia Serpa Osorio-de-Castro; Luiz Júpiter Carneiro de Souza; Felipe Ferre; Daniel Marques Mota; Marcia Ito; Monique Elseviers; Elisangela da Costa Lima; Ivan Ricardo Zimmernan; Izabela Fulone; Monica Da Luz Carvalho-Soares; Luciane Cruz Lopes
Journal:  Front Pharmacol       Date:  2022-01-14       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.